Dexcom (DXCM) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $994.2 million, with 3% organic growth year-over-year, driven by international expansion, new product launches, and record new patient starts, while U.S. performance stabilized late in the quarter.

• Stelo, the first OTC glucose biosensor in the U.S., launched with rapid adoption, and Dexcom ONE+ expanded to 19 countries.

• Chief Commercial Officer announced retirement, with the CEO assuming interim commercial leadership.

• $750 million share repurchase program completed in Q3, reflecting strong capital allocation.

• Ended Q3 with $2.5 billion in cash and equivalents, providing significant financial flexibility.

Financial highlights

• Worldwide revenue was $994.2 million (+2% reported, +3% organic); U.S. revenue declined 2% to $701.9 million, while international revenue grew 12% to $292.3 million.

• Non-GAAP gross profit was $625.9 million (63% margin), down from 64.7% a year ago; GAAP gross margin declined to 59.7%.

• Non-GAAP operating income was $212 million (21.3% margin), down from $238.9 million (24.5%) last year; GAAP operating income was $152 million (15.3% margin).

• Adjusted EBITDA was $300.1 million (30.2% margin), compared to $314.5 million (32.3%) last year; non-GAAP adjusted EBITDA margin was 28.3%.

• Net income was $179.9 million non-GAAP ($0.45 per share) and $134.6 million GAAP ($0.34 per share); cash and equivalents totaled $2.5 billion.

Outlook and guidance

• 2024 revenue guidance reaffirmed at $4.0–$4.05 billion (11–13% organic growth), with margin targets of ~63% gross, ~20% operating, and ~29% adjusted EBITDA.

• 2025 long-range plan targets $4.6 billion revenue and margin improvements, with Stelo and new product launches contributing.

• Management expects continued positive operating cash flows and sufficient liquidity for at least the next 12 months.

• Ongoing investments in R&D and manufacturing capacity expansion in Arizona, Malaysia, and Ireland.

• Rebate eligibility impact peaked in Q3 and is expected to moderate in Q4 and 2025.